ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis

Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis
Literature review current through: Jan 2024.
This topic last updated: Sep 19, 2023.

INTRODUCTION — Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in childhood with symptoms of hyperactivity, impulsivity, and/or inattention. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning [1].

This topic will provide an overview of the treatment and prognosis of ADHD in children. Other topics related to ADHD are presented separately:

(See "Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis".)

(See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis".)

(See "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications".)

(See "Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents".)

(See "Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder".)

(See "Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis".)

DIAGNOSTIC CRITERIA — Diagnostic criteria for ADHD include symptoms of hyperactivity, impulsivity, and/or inattention that occur in more than one setting and affect function (eg, academic, social, emotional, etc). The evaluation and diagnosis of ADHD is discussed separately. (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis".)

GENERAL PRINCIPLES

Care coordination — ADHD is a chronic condition and should be managed in a manner similar to other chronic conditions of childhood [2,3]. In addition to regularly monitoring the effectiveness of therapeutic interventions, it is important for primary care clinicians to provide information to the caregivers and child about ADHD, help the caregivers set specific treatment goals, and offer information regarding local support groups if they are available (table 1) [2,4,5]. (See "Children and youth with special health care needs".)

Regular communication between the caregivers and the teachers is important. This can occur through a daily report card or a weekly communication book.

Involvement of patient and caregivers — Treatment of ADHD may involve behavioral interventions, medication, school-based interventions, or psychological interventions alone or in combination. Decisions regarding the choice of therapy should involve the patient (if at least school-aged) and their caregivers. Together with the treating clinician, the patient and caregivers must evaluate the risks and benefits of the various treatment options to determine the optimal treatment strategy [2,3]. (See 'Treatment modalities' below.)

Target goals — The management of children with ADHD centers upon the achievement of target outcomes that are realistic, achievable, and measurable [6]. Specific target outcomes may change over the course of treatment and should be determined in collaboration with the caregivers, child, and school personnel. Between three and six target outcomes can be addressed at any given time. Progress can be monitored with a daily report card.

Examples of target outcomes include [7]:

Improved relationships with caregivers, teachers, siblings, or peers (eg, plays without fighting at recess)

Improved academic performance (eg, completes academic assignments)

Improved rule following (eg, does not talk back to the teacher)

Treatment of coexisting conditions — As many as one-third of children with ADHD have one or more coexisting condition (eg, learning disorders, oppositional defiant disorder, conduct disorder, anxiety disorder, mood disorders, tics, sleep disorders) [8,9]. It is important to treat coexisting conditions concurrently with ADHD; treatment of coexisting conditions may influence the treatment for ADHD [3]. Adjunctive behavioral, psychological, and pharmacologic interventions may be necessary for managing the full spectrum of symptoms in children with ADHD and coexisting conditions [10].

Treatment of sleep problems may improve ADHD symptoms. In a randomized trial, families of 244 children (5 to 12 years of age) with ADHD and parent-reported moderate to severe sleep problems who met diagnostic criteria for at least one sleep disorder (eg, delayed sleep phase, sleep onset disorder) were assigned to receive a brief behavioral sleep intervention or usual care; 88 percent of children in both groups were receiving pharmacotherapy (predominantly methylphenidate) [11]. The intervention consisted of two consultations about sleep with a trained clinician two weeks apart and a follow-up phone call two weeks later. At the three- and six-month follow-up, children in the intervention group had greater, albeit modest, improvements in ADHD symptoms and teacher-reported behavior than control children. (See "Cognitive and behavioral consequences of sleep disorders in children", section on 'Clinical consequences of sleep deficiency'.)

Indications for referral — ADHD in children 4 to 18 years of age without comorbid conditions can usually be managed by the primary care provider [3]. Indications for referral to or consultation with a specialist (eg, developmental behavioral pediatrician, child neurologist, psychopharmacologist, child psychiatrist, clinical child psychologist) may include [3,4,12]:

Coexisting psychiatric conditions (eg, oppositional defiant disorder, conduct disorder, substance abuse, emotional problems) (see "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Evaluation for coexisting disorders')

Coexisting neurodevelopmental, neurologic, or medical conditions (eg, seizures, tics, autism spectrum disorder, learning disorders, intellectual disabilities, sleep disorder) (see "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Differential diagnosis')

Lack of response to a controlled trial of stimulant therapy or atomoxetine (see "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Dose titration')

Complex psychosocial circumstances (eg, trauma or other adverse childhood experiences)

OVERVIEW OF MANAGEMENT — The recommended treatment strategies for children with ADHD vary according to age [3,13]. The American Academy of Pediatrics [3], American Academy of Child and Adolescent Psychiatry [2], the United Kingdom's National Institute for Health and Care Excellence [14], the Scottish Intercollegiate Guideline Network [13], and the European Network for Hyperkinetic Disorders [15] have developed guidelines or practice parameters for the evaluation and management of children with ADHD. The Society for Developmental and Behavioral Pediatrics have guidelines and process of care algorithms for evaluation and management of children with complex ADHD [10,12]. The recommendations included in this topic review are consistent with the recommendations of these groups. (See 'Society guideline links' below.)

Preschool children — For preschool children (age 4 through 5 years) who meet the diagnostic criteria for ADHD, we recommend parent (caregiver) training in behavior management (PTBM; also known as behavior therapy) rather than medication as the initial therapy [3,13,16]. Behavior therapy can be administered by the caregivers or teachers following consultation with a behavioral therapist. (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Diagnosis' and 'Psychosocial interventions' below.)

The addition of medication to behavior therapy may be indicated if target behaviors do not improve with behavioral therapy alone and the child's function continues to be impaired. Examples of situations in which it may be warranted to add medication to behavioral therapy for preschool children include [10,17]:

Expulsion (or threatened expulsion) from preschool or daycare

Significant risk of injury to self, other children, or caregivers

Strong family history of ADHD

Suspected or established central nervous system injury (eg, prenatal alcohol or cocaine exposure)

ADHD symptoms interfere with other needed therapies

When medication is necessary for preschool children, we suggest methylphenidate rather than amphetamines or nonstimulant medications [2,3,18]. (See "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Preschool children'.)

Some children diagnosed with ADHD during the preschool or early school years may no longer meet criteria for ADHD after school entry or in the later school years [19]. New diagnoses for such children may include autism spectrum disorder, learning disorders, and anxiety, highlighting the importance of monitoring young children diagnosed with ADHD for other neurodevelopmental and behavioral disorders over time. Comprehensive reevaluation during the school years may be warranted. (See 'Prognosis' below.)

School-age children — For most school-aged children and adolescents (≥6 years of age) who meet the diagnostic criteria for ADHD and specific criteria for medication, we suggest initial treatment with stimulant medication combined with PTBM (behavior therapy) to improve core symptoms and target outcomes [2,3,13,15,16,20,21]. However, nonstimulant medications may be more appropriate for certain children. Comorbid conditions must be considered in selecting a specific treatment approach [10].

The values and preferences of the patient and caregivers are critical factors in deciding whether to initiate medication [3]. The decision of caregivers who choose to decline medication must be respected. (See "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Choice of agent' and 'Psychosocial interventions' below.)

Children who do not meet ADHD criteria — We recommend behavioral interventions for children with problematic behavior who do not meet the diagnostic criteria for ADHD. (See 'Psychosocial interventions' below.)

Monitoring — ADHD is a chronic disease [3]. Children undergoing treatment for ADHD should be monitored regularly for adherence to the treatment plan, adverse effects of therapy (for those on medications), and response to therapy (eg, the achievement of target goals and the occurrence of core symptoms) [2-4,22]. If the selected management strategy does not result in attainment of the target outcome, the original diagnosis, comorbid conditions, and adherence to management plan should be reevaluated [2]. (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Evaluation'.)

Adverse effects of medications and monitoring for adverse effects of medications are discussed separately. (See "Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents" and "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Managing stimulant adverse effects'.)

The frequency of follow-up visits depends upon whether the child is receiving medication and how well the core symptoms and target behaviors are being controlled. Children who are not receiving medication should be seen at least twice per year, particularly during critical transitions (eg, into middle school or high school). The monitoring schedule for children receiving medication depends upon the stage of pharmacotherapy [6]. It may range from weekly during the titration stage to every three or six months during the maintenance phase, depending upon adherence, coexisting conditions, and the persistence of symptoms. (See "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Dose titration'.)

Response to treatment — Response to treatment is demonstrated by objective measurement of reduction in core symptoms and/or improvement in target goals (eg, 40 to 50 percent reduction in core symptoms compared with baseline; decreased proportion of missing assignments from 60 to 20 percent per week) [6]. Core symptoms can be monitored through the use of ADHD-specific rating scales (table 2); target symptoms can be monitored through a daily report card or periodic narrative reports from the child's teacher [6,23]. Caregiver reports correlate poorly with teacher reports and cannot be used as a proxy for teacher reports [24,25]. A toolkit that provides information about daily report cards is available through the National Institute for Children's Health Quality.

Inadequate or lack of response to treatment may be due to [2,6]:

Coexisting conditions (eg, language or learning disorders, mental health disorder, psychosocial stressor) (see "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Evaluation for coexisting disorders')

Nonadherence to the treatment plan

Incorrect or incomplete diagnosis (see "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Differential diagnosis')

For children with inadequate or lack of response to treatment, repetition of the diagnostic evaluation may be warranted, with increased focus on coexisting conditions that are associated with ADHD or mimic its symptoms (eg, sleep disorders, epilepsy, learning disorders, etc). The nonspecific improvement in behavior that occurs with stimulant medication can mask other problems and/or delay the use of more appropriate interventions (eg, serotonin reuptake inhibitor for depression) [22,26]. (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Evaluation'.)

TREATMENT MODALITIES

Psychosocial interventions — Psychosocial interventions include modifications in the physical and social environment that are designed to change behavior using rewards and nonpunitive consequences [3,27]. Behavioral management techniques that are used for children with ADHD include positive reinforcement, time-out, response cost (withdrawing rewards or privileges when unwanted or problem behavior occurs), and token economy (a combination of positive reinforcement and response cost) [28].

Psychosocial interventions, particularly behavioral ones, are preferred to medication as the initial intervention for preschool children with ADHD and are adjuncts to medication for school-aged children and adolescents [3,14,29-31]. Behavioral interventions also can be used for children who have problems with inattention, hyperactivity, or impulsivity but do not meet criteria for ADHD [3]. (See "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Prerequisites' and 'School-age children' above.)

Parent (or caregiver) training in behavior management (PTBM) is aimed at improving parent-child relationships through enhanced parenting techniques [17]. Behavioral interventions are most effective if caregivers understand the principles of behavior therapy (ie, identification of antecedents and altering the consequences of behavior) and the techniques are consistently implemented [17,28]. PTBM therapists or programs (typically eight or more sessions) are available in many communities [6,32]. Clinicians can request references for a suitable behavioral therapist from professional organizations (eg, Association for Behavior and Cognitive Therapies) or ADHD advocacy organizations (eg, Children and Adults with Attention Deficit Hyperactivity Disorder). The Centers for Disease Control and Prevention (CDC) provides additional resources for parents seeking PTBM [32].

Behavioral interventions and environmental changes that can be used by caregivers or teachers to shape the behavior of children with ADHD include [33]:

Maintaining a daily schedule

Keeping environmental distractions to a minimum

Providing specific and logical places for the child to keep their schoolwork, toys, and clothes

Setting small, reachable goals (see 'Target goals' above)

Rewarding positive behavior (eg, with a "token economy")

Identifying unintentional reinforcement of negative behaviors

Using charts and checklists to help the child stay "on task"

Limiting choices

Finding activities in which the child can be successful (eg, hobbies, sports)

Using calm discipline (eg, time out, distraction, removing the child from the situation)

Additional tips for caregivers of children age 6 to 12 years are available through the National Institute for Children's Health Quality toolkit, free with registration, and the CDC. (See 'Resources' below.)

Standardized training programs for caregivers of preschool children with disruptive behavior disorders (including symptoms of ADHD) that have been evaluated in systematic reviews include [27,34,35]:

Incredible Years Parenting Program (www.incredibleyears.com/index.asp)

New Forest Parenting Program (specifically designed to address ADHD symptoms)

Positive Parenting Program (Triple P)

Parent-Child Interaction Therapy

Helping the Noncompliant Child

Adolescents may also benefit from direct skills training [3], which is intended to build the adolescent's skills to meet age-appropriate expectations and functional demands. Direct skills training may include homework organization, time management, study skills, and self-monitoring skills. A systematic review of psychosocial treatment programs for adolescents found small- to medium-sized improvements in parent-rated ADHD symptoms, co-occurring behavioral and emotional symptoms, and interpersonal functioning, but more robust improvements in academic and organizational skills [21].

Evidence supporting behavioral interventions for ADHD is limited. In an individual participant data meta-analysis that included 2233 children and adolescents with ADHD, behavioral interventions (eg, PTBM, classroom interventions, skills training) had small to moderate effects on individual and collective symptoms of ADHD and global impairment in unblinded assessments by parents or teachers [36]. In a separate meta-analysis of randomized trials, PTBM had small to moderate effects on parental outcomes (eg, improved competence or mental health, decreased negative parenting [eg, corporal punishment, harsh discipline]) compared with control [37]. Techniques focused on changing antecedent behavior and reinforcement appeared to be most effective.

Studies of behavior therapy in other populations of children provide indirect evidence of benefit. In a meta-analysis of eight studies in preschool children with disruptive behavior disorders (including children at risk for ADHD), PTBM was associated with improved parent-reported child behavior (standardized mean difference -0.68, 95% CI -0.88 to -0.47) [27]. The standardized mean difference (also called the effect size) describes the extent to which the performance in the treatment group differed from that in the control group; by consensus, differences of 0.2, 0.5, and 0.8 are considered small, moderate, and large, respectively. The addition of school or daycare interventions to parent-child behavior therapy appeared to have some benefit for children from families of lower socioeconomic status. The long-term effects of behavior therapy for ADHD have not been determined [18].

In most systematic reviews, behavioral interventions alone do not appear to reduce the core symptoms of ADHD in school-aged children but may improve other problem behaviors (eg, aggression, caregiver-child relations) [38-42]. However, two systematic reviews found behavioral interventions to be effective [43,44]. The conclusions of the systematic reviews are limited by the quality of the included studies [39,40,45,46]. Problems include insufficient description of the intervention and the complexity of the child's family, school, social, and peer environments [31].

Pharmacotherapy — Medications, with or without psychosocial interventions, are the first-line therapy for school-aged children (≥6 years) and adolescents who meet diagnostic criteria for ADHD (table 3) [3]. (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Diagnosis'.)

Medications may be used as an adjunct to behavioral interventions for preschool children (4 through 5 years) who fail to respond to behavioral interventions alone. However, the values and preferences of the patient and caregivers are critical factors in deciding whether to initiate medication [3]. The decision of caregivers who choose to decline medication must be respected. (See 'Overview of management' above.)

Treatment of ADHD with medications, including the choice of agent and dose titration, is discussed separately. (See "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications".)

Combination therapy — Combination therapy uses both psychosocial interventions and medications. Combination therapy may be warranted in preschool children who do not respond to behavioral interventions alone [2]. In a systematic review and a meta-analysis, combination therapy with medications and behavior/psychological therapy was superior to behavior/psychological therapy alone [39,47]. (See 'Preschool children' above.)

Combination therapy may be beneficial for school-aged children and adolescents who have a suboptimal response to pharmacotherapy, have a coexisting condition, or experience stressors in family life [2]. In systematic reviews of randomized trials (including the Multimodal Treatment Study of Children with ADHD), combined medication and behavior treatment was no more effective than medication treatment alone in improving core symptoms of ADHD [39,47,48]. However, children receiving combined treatment may require lower doses of medication and achieve greater improvement in non-ADHD symptoms (eg, oppositional/aggressive, internalizing, teacher-rated social skills, caregiver-child relations, and reading achievement) than children receiving medication alone [21,30,48]. (See 'School-age children' above.)

School-based interventions — School-based interventions may include the provision of tutoring or resource room support (either in an exclusive setting or within the classroom [ie, inclusion classes]), classroom modifications, accommodations, behavioral interventions, or direct skills training [3,21,33,49].

Classroom modifications and accommodations may include having assignments written on the board, sitting near the teacher, having extended time to complete tasks, being allowed to take tests in a less distracting environment, or receiving a private signal from the teacher when the child is "off-task." The teacher's completion of a daily report card facilitates the monitoring of symptoms and the need for changes in the treatment plan. (See 'Response to treatment' above.)

The school also may provide behavior management programs that target ADHD symptoms and/or enhanced academic and social function [3]. Information for teachers of children with ADHD is available through Children and Adults with Attention-Deficit/Hyperactivity Disorder.

Evidence supporting school-based interventions is limited [50,51]. A systematic review [50] found two cohort studies (and one extension) that demonstrated that classroom-based programs to enhance academic skills were effective in improving achievement scores in multiple domains, but the benefits were sustained only as long as the intervention is continued [52-54].

In the United States, ADHD is considered to be a disability under the Individuals with Disabilities Education Act (IDEA [PL-101-476]). Under IDEA, children with ADHD may qualify for special education or related services. Alternatively, they may qualify for appropriate accommodations within the regular classroom setting under Section 504 of the Rehabilitation Act of 1973 (table 4) [49]. In addition, the Americans with Disabilities Act may provide individuals with ADHD reasonable accommodations in secular private schools and post-secondary education (table 5). The completion of a daily report card or a "communication book" to facilitate communication between the caregivers and the teachers may be suggested as an accommodation under a 504 plan. (See "Definitions of specific learning disorder and laws pertaining to learning disorders in the United States", section on 'Laws affecting the education of students with disabilities' and "Children and youth with special health care needs", section on 'School-based services'.)

Social skills training — Deficits in social skills and problems with peers require direct targeting over the long-term [55]. Social skills deficits can be addressed through social skills groups or similar interventions (in or out of the school setting).

Psychotherapy interventions — Psychotherapy interventions are distinct from behavioral interventions. Psychotherapy interventions are directed toward the child (rather than the caregiver or environment) and designed to change the child's emotional status (eg, play therapy) or thought patterns (eg, cognitive-behavior therapy, cognitive therapy).

We generally suggest against psychotherapy interventions for children with ADHD unless they have coexisting conditions that require psychotherapy interventions (eg, depression, anxiety, social deficits). In randomized trials and systematic reviews, psychotherapy interventions have not been proven beneficial for the core symptoms of ADHD in children [18,42,56]. Gains achieved with psychotherapy interventions in the treatment setting usually do not transfer to other settings (eg, classroom or home).

However, psychotherapy interventions may be helpful in addressing coexisting conditions or skill deficits. Play-based interventions may improve social skills in children with ADHD [57,58]. Cognitive-behavioral therapy (CBT) may improve organizational/planning skills, cognitive function, and/or coexisting psychiatric problems in adolescents with ADHD and may be a helpful adjunct to medications [59-64].

UNPROVEN INTERVENTIONS

Physical activity — At least 60 minutes of moderate to vigorous activity per day is recommended for all children ≥6 years of age, not just those with ADHD [65]. Regular physical activity has been associated with improved cardiovascular health, psychosocial well-being, and cognitive performance. (See "Physical activity and strength training in children and adolescents: An overview", section on 'Physical activity'.)

We support this recommendation for children with ADHD. In systematic reviews and small open-label controlled trials with heterogeneous designs, a range of physical activities (eg, yoga, team sports, aerobic activity, guided walks) have been associated with improvement in the core symptoms of ADHD with little risk of harm [66-75]. Small trials also suggest that aerobic exercise improves neurocognitive function [66] and increases the effectiveness of stimulant medications [76]. In a meta-analysis of five comparison studies (144 participants age 5 to 25 years) [69,70,76-78], physical activity in children, adolescents, and young adults with ADHD improved cognitive function with a mean effect size of 0.93 (95% CI 0.48-1.45) [64]. Additional studies are needed to determine which types, duration, intensity, and frequency of exercise are most effective.

Dietary interventions

Elimination diets — We generally do not suggest elimination diets for children with ADHD, but decisions regarding trials of dietary interventions for ADHD must be made on a case-by-case basis. Some experts suggest that a short (no more than five-week) trial of an elimination diet may be warranted for certain children (eg, those whose caregivers are concerned about the use of and potential side effects of pharmacologic agents and are motivated to adhere to the diet) [79-81]. If the decision is made to try an elimination diet, the diet should be supervised by the child's health care provider and a dietician to ensure adequate nutritional intake. If behavior improves during the elimination diet, restricted foods can be added back weekly, one component at a time, to identify problematic foods that should be excluded from a less restrictive permanent diet.

The influence of diet on attention, hyperactivity, and behavior is controversial. Dietary factors (eg, food additives, food allergy or intolerance, etc) generally do not impact behavior to a clinically significant level and do not account for the majority of cases of ADHD. However, a small subset of children may demonstrate mild adverse behavioral effects in response to particular dietary components and improvements in behavior when these components are eliminated. (See "Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis", section on 'Dietary influences'.)

Systematic reviews and meta-analyses of randomized trials with methodologic limitations suggest that some children with ADHD respond favorably to elimination diets [82-87]. In a 2012 meta-analysis of five randomized crossover studies, restriction diets had a small impact on ADHD symptom reduction in children (effect size 0.29, 95% CI 0.16-0.52) [84]. Masked challenge with specific food colors had a small effect on parent-reported ADHD symptoms (20 studies, 794 participants, effect size 0.18, 95% CI 0.08-0.29), and a non-significant effect on teacher-reported symptoms (10 studies, 323 participants effect size 0.07, 95% CI -0.03 to 0.18). This discrepancy between parent and health professional/teacher report of symptoms has been noted in other studies [83,88]. The long-term effects of dietary elimination on nutritional status are unknown [79].

Clinical guidelines and practice parameters from the American Academy of Pediatrics [3], the American Academy of Allergy, Asthma & Immunology [89], and the United Kingdom's National Institute for Health and Care Excellence (NICE) [14] do not routinely recommend elimination diets for the treatment of ADHD. However, the NICE guidelines indicate that referral to a dietician may be warranted if perceived links between specific foods or beverages and behavior are corroborated with a food diary [14].

Essential fatty acid supplementation — We do not suggest essential fatty acid supplementation to improve core symptoms in children with ADHD. Some studies have noted decreased fatty acid concentrations in the serum of children with ADHD [90-94]. However, evidence that fatty acid supplementation improves core symptoms in children with ADHD is limited [87,95-99]. Meta-analyses of randomized trials have conflicting results [18,42,95,97,99], and clear evidence of benefit is lacking [100]. Fatty acid supplementation is unlikely to be harmful.

Possible explanations for the inconsistent findings in the meta-analyses include differences in population (children diagnosed with ADHD versus children with ADHD symptoms) and outcome measures (separate versus pooled caregiver- and teacher-reported symptoms).

Mindfulness — Mindfulness refers to heightened or complete awareness of one's thoughts, emotions, or experiences on a moment-to-moment basis to increase self-regulation. In small unblinded pilot studies, 8 to 12 weeks of mindfulness training for children with ADHD and/or their caregivers was associated with decreased caregiver-rated ADHD symptoms and caregiver stress [101-103]. These observations indicate that mindfulness may be beneficial as an adjunct to a comprehensive ADHD management program that includes behavioral interventions and pharmacotherapy as indicated. However, larger and more robust clinical studies are needed to determine the optimal patient population and approach.

Video game-based interventions — Limited evidence supports the use of a video game-based intervention (Endeavor Rx, AKL-T01) to improve attention function in children with ADHD [104,105]. This intervention is available by prescription for children age 8 to 12 years with primarily the inattentive or combined presentation of ADHD and is intended to be used with other ADHD treatment modalities [106]. Insurance authorization is required.

In a randomized trial that compared a four-week course (five sessions per day, five days per week) of AKL-T01 with a digital control intervention in 348 children with ADHD who were medication naïve or discontinued their medication and who met a threshold for cognitive deficits in attention, AKL-T01 modestly improved attention as assessed by greater mean change from baseline on the Test of Variables of Attention (TOVA) [104]. In a subsequent open-label study in children with ADHD but no entry threshold for cognitive deficit in attention, a four-week course of AKL-T01 improved ADHD-related impairment (as assessed by the Impairment Rating Scale) in children with ADHD who were treated with stimulants as well as those not treated with stimulants [105]; treatment benefits were sustained during a four-week pause in treatment and improved with a second course of treatment. Although these studies suggest that video game-based intervention may improve some cognitive skills, the skills may not be generalizable (eg, to interpersonal or academic function) [107].

Trigeminal nerve stimulation — We do not suggest trigeminal nerve stimulation (TNS) for the treatment of ADHD in children. Clinical experience is limited [108,109].

TNS is a noninvasive neuromodulation technique based on the hypothesis that electrical stimulation of the trigeminal nerve (supraorbital branch) affects the areas of the brain thought to be involved in ADHD [110,111].

Although a randomized trial found that TNS improved scores on ADHD-IV Rating Scales and Clinical Global Impression scales over four weeks, only 62 children were included [108]. No clinically important adverse effects were reported. Additional studies are necessary to confirm efficacy and safety, and to determine which of children with ADHD are most likely to benefit as well as the optimal regimen [111].

Other alternative therapies — Complementary and alternative medicine (CAM) therapies may be considered or employed by as many as 64 percent of patients with ADHD [112]. CAM therapies often are used by patients without the explicit knowledge of the primary care provider [113-115]. It is important for primary care providers to ask their patients whether they have tried any CAM therapies for ADHD so that the risks and benefits of such therapies can be discussed [116].

CAM therapies other than physical activity, elimination diets, fatty acid supplementation, and mindfulness that have been suggested in the management of ADHD include vision training, megavitamins, herbal and mineral supplements (eg, St. John's wort), neurofeedback/biofeedback, chelation, and applied kinesiology, among others. Most of these interventions have not been proven efficacious in high-quality randomized controlled trials [42,64,117-129]. We do not routinely suggest these interventions for children with ADHD. (See "Clinical use of St. John's wort", section on 'Other conditions'.)

Several alternative therapies, including chelation and megavitamins, may have serious adverse effects or harmful interactions with other herbs, vitamins, supplements, and prescribed medications [3,130-132]. Additional harms include the potential failure and setback for the child when symptoms and problems persist, as well as unnecessary expenses, time cost, and opportunity cost when evidence-based ADHD treatments are delayed [117].

Clinicians can help caregivers who choose to explore CAM therapies to make thoughtful choices by [6,133]:

Reviewing the stated goals or effects for a given treatment

Reviewing the evidence of benefits and potential adverse effects, including drug-supplement interactions

Encouraging caregivers who want to try CAM therapies to try them one at a time and to monitor target goals and core symptoms to determine effect

Encouraging caregivers to determine a time frame in which they expect behavior changes to occur

Encouraging caregivers to use evidence-based behavioral interventions and/or medications at the same time that they are exploring CAM therapies

The clinician also can try to redirect patients and caregivers who are using potentially harmful CAM therapies (eg, megavitamins) to safer (if still unproven) lifestyle therapies (eg, yoga, massage therapy). (See "Complementary and integrative health in pediatrics", section on 'Discussing complementary therapies with patients and families'.)

PROGNOSIS — Most of the information about prognosis in children with ADHD is derived from small cohort studies of male patients who were evaluated and treated for ADHD in psychiatric clinics [115,134-141]. The generalizability of the information to other patient groups is limited. Long-term follow-up (six to eight years) of the Multimodal Treatment study of children with ADHD (MTA) study cohort suggests that functioning during adolescence is predicted by the initial clinical presentation (including severity of symptoms and comorbid conduct problems), intellect, social advantage, and the strength of ADHD response to any mode of treatment [142]. Follow-up into early adulthood (approximately 16 years after enrollment at a mean age of approximately 25 years) suggests that functioning in early adulthood is predicted by persistence of symptoms, baseline ADHD severity, intelligence quotient, and comorbidity [143,144], and that most children have a course with intermittent periods of remission and recurrence [145]. Early and effective management and support may be helpful in improving adult outcomes.

Persistence of symptoms – For most children with ADHD, ADHD symptoms fluctuate between childhood and young adulthood with intermittent periods of remission and recurrence. In prospective follow-up, 558 participants in the Multimodal Treatment Study of ADHD had eight assessments over time ranging from 2 to 16 years after baseline [145]. At the study endpoint (mean age of 25.1 years), 64 percent had fluctuating periods of remission and recurrence (full or partial), 16 percent had sustained partial remission, 9 percent had sustained remission, and 11 percent had persistent ADHD (met ADHD criteria at all follow-ups). At any given follow-up, 40 to 50 percent of participants met ADHD criteria, consistent with findings from earlier studies [146-151]. Factors associated with persistence of symptoms into adulthood include the severity of initial symptoms, coexisting mental health disorders, and parental mental health disorders [152,153]. (See "Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis".)

In another prospective study, 70 percent of 88 children diagnosed with ADHD at a tertiary care clinic before age seven continued to meet criteria for ADHD four to nine years later (median interval seven years) [19]. Among the 26 children who no longer met criteria for ADHD, new diagnoses included autism spectrum disorder (10 children), learning disorder (3 children), and anxiety disorder (2 children), highlighting the importance of monitoring young children diagnosed with ADHD for symptoms of other neurodevelopmental and behavioral disorders. (See 'Preschool children' above.)

Injury and self-injury – Children with ADHD or symptoms of ADHD are at greater risk for incurring intentional and unintentional injury than children without these symptoms [146,151,154-160]. Treatment with stimulant medications may mitigate this risk [161-164]. In a review of medical, pharmaceutical, and disability claims for injuries or poisoning treatments, individuals with ADHD were more likely to have at least one claim related to unintentional injury than controls (28 versus 19 percent for children, 32 versus 23 percent for adolescents, and 38 versus 18 percent for adults) [154]. In nationwide cohort studies, ADHD was independently associated with increased mortality in children, adolescents, and adults [159,165]; most of the deaths were caused by unnatural causes, particularly unintentional injuries.

In a prospective study of 140 females with ADHD diagnosed at age 6 to 12 years (93 with combined type [ADHD-C], 47 with inattentive type [ADHD-I]), those with ADHD-C were more likely to have attempted suicide during the 10-year follow-up than those with ADHD-I or controls (22, 8, and 6 percent, respectively) [151]. Self-injury was also more common among females with ADHD-C than females with ADHD-I or controls (51, 29, and 19 percent, respectively).

Driving – Adolescents with ADHD are more likely than those without the disorder to have motor vehicle crashes (relative risk 1.9, 95% CI 1.4-2.5 in a meta-analysis of five observational studies) [166,167]. The risk is particularly increased in the first months after obtaining a driver's license and may be related to risky driving behaviors (eg, speeding, not wearing a seatbelt, alcohol and/or drug use) [168]. Adolescents with ADHD also are more likely to have their driving licenses suspended or revoked. In randomized trials, driving performance improves with stimulant medication [166,169-171].

Education – Follow-up studies of children with ADHD into adolescence consistently indicate impaired academic functioning (eg, completion of less schooling, lower achievement scores, failure of more courses) compared with controls [63,114,115,134,150,151,172-176]. This is particularly true for children with the inattentive or combined presentation of ADHD [177]. In the few studies in which subjects were followed into adulthood, the findings persisted (25 to 33 percent of probands versus 1 to 9 percent of controls dropped out of high school; 15 to 19 percent of probands versus 50 to 64 percent of controls had completed a bachelor's or higher level degree) [134,137,138,141,178]. Impaired academic function appears to persist, even in those children who no longer meet criteria for diagnosis of ADHD in adolescence or adulthood [115].

Substance use – Children with ADHD may be at increased risk of engaging in substance use during adolescence and adulthood, particularly if they present with comorbid conduct disorder (CD) or oppositional defiant disorder (ODD). (See "Substance use disorder in adolescents: Epidemiology, clinical features, assessment, and diagnosis", section on 'Risk factors'.)

Although individual longitudinal studies have had inconsistent results, a 2011 systematic review and meta-analysis of 27 prospective longitudinal studies found that compared with children without ADHD, children with ADHD were at increased risk for [179]:

Ever using nicotine (odd ratio [OR] 2.1, 95% CI 1.7-2.6) and nicotine dependence in adolescence or adulthood (OR 2.8, 95% CI 2.4-3.3)

Alcohol use disorder (OR 1.7, 95% CI 1.4-2.2), but not ever use of alcohol

Ever using marijuana (OR 2.8, 95% CI 1.6-4.7) and marijuana use disorder (OR 2.3, 95% CI 1.3-4.0)

Cocaine use disorder (OR 2.1, 95% CI 1.4-3.0)

General illicit drug use (substances not explicitly specified, OR 2.6, 95% CI 1.8-3.9)

The effect sizes did not differ by average age at follow-up, sex, race, population (eg, general versus referral), or diagnostic criteria for ADHD. However, the majority of these studies did not assess comorbid ODD or CD and, based on 10 studies, children with comorbid ADHD and ODD or CD had more substance abuse problems than children with only ADHD and controls [179]. In fact, 2 of these 10 studies report no increased risk for substance abuse in ADHD beyond that explained by comorbid ODD and CD.

The mechanism for the association between ADHD and substance use is not clear [180]. Proposed theories include impulsivity, poor judgment, and biologic vulnerability (perhaps related to dopamine transmission).

The risk of engaging in substance use in adolescence or adulthood does not appear to be affected by the pharmacologic treatment of ADHD [181,182]. In a 2013 meta-analysis of 15 longitudinal studies (2565 participants), stimulant treatment neither protected against nor increased the risk of subsequent substance use disorders [182]. These findings differ from those of a 2003 meta-analysis of six studies, which found a reduced risk of substance abuse disorders among individuals with ADHD who were treated with medications compared with those who were not [183]. Additional support for a lack of effect is provided by eight-year follow-up of participants in the MTA (not included in the meta-analyses), in which children (7 to 9.9 years old at the time of enrollment) were randomly assigned to 14 months of medication, behavior therapy, combined medication and behavioral therapy, or standard community care [181]. No effect of medication for ADHD on subsequent substance use was found – whether analyzed by original treatment group, medication at follow-up, or cumulative stimulant therapy.

The lack of association between stimulant use and risk of subsequent substance use may not hold for youth who misuse prescription stimulants. A 2023 national longitudinal study of more than 5000 adolescents enrolled in 12th grade and followed for six years evaluated the association between stimulant use and subsequent cocaine or methamphetamine use [184]. Participants who used stimulants as prescribed for ADHD therapy at study entry were no more likely to start using cocaine or methamphetamine over the six-year follow-up period than participants who did not use stimulants. However, those who reported prescription stimulant misuse but no history of stimulant treatment for ADHD at study entry were more likely to have initiated cocaine or methamphetamine use compared with those who did not use stimulants at all (OR 2.6, 95% CI 1.5-4.6).

Employment – In studies that followed children with ADHD into early adulthood, the rate of employment of ADHD probands did not differ from that of controls [137,138]. However, in a prospective male cohort that was followed for 33 years (mean age 41 years), fewer probands than controls were employed (83 versus 95 percent) [141]. Probands were reported to have lower status jobs and to perform poorly compared with controls when rated by their employers in various areas of work performance [134,141].

Antisocial personality – Children who have ADHD are at increased risk to develop antisocial personality disorder (ASPD) and behaviors in adulthood [134,141,185]. In studies that followed children with ADHD into adulthood, the prevalence of ASPD ranges from 12 to 23 percent in probands (predominantly with the hyperactive-impulsive presentation of ADHD) versus 2 to 3 percent in controls [135,137,138,141].

The increased risk of developing ASPD appears to be independent of comorbid conduct disorder in childhood because children with comorbid problems were excluded from several study cohorts [136,137]. In an observational study, 54 percent of 147 ADHD patients self-reported having been arrested at least once by age 21 years (compared with 37 percent of 73 community controls); 24 percent of ADHD patients had been arrested for misdemeanors (compared with 11 percent of controls) and 27 percent for felony (compared with 11 percent of controls) [185].

RESOURCES — The National Institute for Children's Health Quality (NICHQ), in conjunction with North Carolina's Center for Child Health Improvement and the American Academy of Pediatrics (AAP), has developed a toolkit to assist primary care practitioners in the evaluation and management of school-age children with ADHD. The toolkit includes information for caregivers, copies of ADHD-specific questionnaires for caregivers and teachers, and an initial primary care evaluation form. It can be downloaded without charge through the NICHQ but may require registration. A revised edition of the toolkit, which also includes tools and resources for preschool children and adolescents, is available for purchase through the AAP.

Resources for caregivers of children with ADHD are provided in the table (table 1).

Information for teachers of children with ADHD is available through Children and Adults with Attention-Deficit/Hyperactivity Disorder.

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Attention deficit hyperactivity disorder".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)

Basics topic (see "Patient education: Attention deficit hyperactivity disorder (ADHD) in children (The Basics)")

Beyond the Basics topics (see "Patient education: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)" and "Patient education: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

General principles

Attention deficit hyperactivity disorder (ADHD) is a chronic condition; education of patients, caregivers, and teachers regarding the diagnosis is an integral part of treatment. Management centers on the achievement of target outcomes, which are chosen in collaboration with the child, caregivers, and school personnel. Coexisting conditions must be treated concurrently with ADHD. (See 'General principles' above.)

Treatment of ADHD may involve psychosocial interventions, medication, and/or educational interventions, alone or in combination. Decisions regarding the choice of therapy should involve the patient and their caregivers. (See 'Involvement of patient and caregivers' above.)

ADHD in children 4 to 18 years of age without comorbid conditions can usually be managed by the primary care provider. Indications for referral to or consultation with a specialist (eg, developmental behavioral pediatrician, child neurologist, psychopharmacologist, child psychiatrist, clinical child psychologist) may include (see 'Indications for referral' above):

-Coexisting psychiatric conditions (eg, oppositional defiant disorder, conduct disorder, substance abuse, emotional problems)

-Coexisting neurologic or medical conditions (eg, seizures, tics, autism spectrum disorder, sleep disorder)

-Lack of response to a controlled trial of stimulant therapy or atomoxetine

-Complex psychosocial context

Management approach

Preschool children – For preschool children (age 4 through 5 years) who meet the diagnostic criteria for ADHD, we recommend parent (or caregiver) training in behavior management (PTBM) rather than medication as the initial therapy (Grade 1A). The addition of medication to PTBM may be indicated if target behaviors do not improve with behavioral therapy and the child's function continues to be impaired. When medication is necessary for preschool children, we suggest methylphenidate rather than amphetamines or nonstimulants (Grade 2B). (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Diagnosis' and 'Preschool children' above and "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Preschool children'.)

School-aged children and adolescents – For most school-aged children (≥6 years) and adolescents with ADHD who meet specific criteria (table 3), we suggest treatment with medication rather than behavior therapy alone or no intervention (Grade 2A). However, decisions regarding the choice of therapy should involve the patient and their caregivers. When the decision is made to try medications, we suggest a stimulant as the first line agent (Grade 2B). (See 'School-age children' above and 'Pharmacotherapy' above and "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Choice of agent'.)

For school-aged children (≥6 years) and adolescents with ADHD, we suggest that psychosocial interventions be added to medication therapy (Grade 2C). Adding psychosocial interventions to stimulant therapy in school-aged children and adolescents does not provide additional benefit for core symptoms of ADHD, but may affect symptoms of coexisting conditions (eg, oppositional/aggressive behavior) and lower the dose of stimulant therapy necessary to achieve the desired effects. (See 'Combination therapy' above.)

Monitoring – Children being treated for ADHD should be monitored regularly for adherence to the treatment plan, achievement of target goals, occurrence of core symptoms, and adverse effects of therapy. The frequency of follow-up depends upon the management strategy. (See 'Monitoring' above.)

School-based interventions – Children with ADHD may require changes in their educational programming, including tutoring, resource room support (either in an exclusive setting or within the classroom), classroom modifications, or direct skills training for adolescents. (See 'School-based interventions' above.)

Dietary interventions – We suggest not using elimination diets for most children with ADHD (Grade 2C). However, a short trial (no more than five weeks) of an elimination diet may be an option for children with ADHD whose caregivers are concerned about the use and potential side effects of pharmacologic agents and are motivated to comply with the diet. (See 'Elimination diets' above.)

We suggest not using essential fatty acid supplementation for children with ADHD (Grade 2C). (See 'Essential fatty acid supplementation' above.)

Prognosis – For most children with ADHD, ADHD symptoms fluctuate between childhood and young adulthood with intermittent periods of remission and recurrence. ADHD diagnosed in childhood is associated with increased rates of intentional and unintentional injury, substance use (particularly in those with comorbid oppositional defiant disorder or conduct disorder), and motor vehicle crashes among those who drive. (See 'Prognosis' above.)

  1. American Psychiatric Association. Attention-deficit/hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington, VA 2013. p.59.
  2. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.
  3. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 2019; 144.
  4. Hill P, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001; 84:404.
  5. Jessop DJ, Stein RE. Providing comprehensive health care to children with chronic illness. Pediatrics 1994; 93:602.
  6. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Supplemental information. Available at https://pediatrics.aappublications.org/content/suppl/2019/09/18/peds.2019-2528.DCSupplemental (Accessed on October 09, 2019).
  7. American Academy of Pediatrics, National Initiative for Children's Healthcare Quality. How to establish a school-home daily report card. http://www.nichq.org/toolkits_publications/complete_adhd/12HowToEstabSchlHomeDailyRepCa.pdf (Accessed on November 17, 2011).
  8. Green M, Wong M, Atkins D, et al. Diagnosis of Attention Deficit/Hyperactivity Disorder. Technical Review 3. AHCPR publication 99-0050, US Dept of Health and Human Services; Agency for Health Care Policy and Research, Rockville, MD 1999.
  9. Horst RO, Hendren RL. Integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD). Essent Psychopharmacol 2005; 6:250.
  10. Barbaresi WJ, Campbell L, Diekroger EA, et al. The Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder: Process of Care Algorithms. J Dev Behav Pediatr 2020; 41 Suppl 2S:S58.
  11. Hiscock H, Sciberras E, Mensah F, et al. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial. BMJ 2015; 350:h68.
  12. Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr 2020; 41 Suppl 2S:S35.
  13. Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people. www.sign.ac.uk/guidelines/fulltext/112/index.html (Accessed on December 12, 2011).
  14. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: Diagnosis and management. NICE guideline [NG87], March 2018. https://www.nice.org.uk/guidance/NG87 (Accessed on October 09, 2019).
  15. Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1:I7.
  16. Feldman ME, Charach A, Bélanger SA. ADHD in children and youth: Part 2-Treatment. Paediatr Child Health 2018; 23:462.
  17. Kaplan A, Adesman A. Clinical diagnosis and management of attention deficit hyperactivity disorder in preschool children. Curr Opin Pediatr 2011; 23:684.
  18. Kemper AR, Maslow GR, Hill S, et al. Attention deficit hyperactivity disorder: Diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 203. AHRQ Publication No. 18-EHC005-EF. Agency for Healthcare Research and Quality, Rockville, MD, January 2018. Available at: https://effectivehealthcare.ahrq.gov/opics/adhd-update/systematic-review-2018 (Accessed on January 30, 2018).
  19. Law EC, Sideridis GD, Prock LA, Sheridan MA. Attention-deficit/hyperactivity disorder in young children: predictors of diagnostic stability. Pediatrics 2014; 133:659.
  20. Harpin VA. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 2008; 93:58.
  21. Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. JAMA 2016; 315:1997.
  22. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279:1100.
  23. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998; 59 Suppl 7:24.
  24. Lavigne JV, Dulcan MK, LeBailly SA, Binns HJ. Can parent reports serve as a proxy for teacher ratings in medication management of attention-deficit hyperactivity disorder? J Dev Behav Pediatr 2012; 33:336.
  25. Wolraich ML, Lambert EW, Bickman L, et al. Assessing the impact of parent and teacher agreement on diagnosing attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004; 25:41.
  26. Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:40.
  27. Charach A, Carson P, Fox S, et al. Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics 2013; 131:e1584.
  28. Floet AM, Scheiner C, Grossman L. Attention-deficit/hyperactivity disorder. Pediatr Rev 2010; 31:56.
  29. Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry 1999; 38:578.
  30. Carlson CL, Pelham WE Jr, Milich R, Dixon J. Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol 1992; 20:213.
  31. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997; 36:85S.
  32. Centers for Disease Control and Prevention. Parent training in behavior management for ADHD. https://www.cdc.gov/ncbddd/adhd/behavior-therapy.html (Accessed on March 24, 2022).
  33. Understanding ADHD. Information for parents about attention-deficit/hyperactivity disorder. American Academy of Pediatrics, Elk Grove Village, IL 2001.
  34. COUNCIL ON EARLY CHILDHOOD, COMMITTEE ON PSYCHOSOCIAL ASPECTS OF CHILD AND FAMILY HEALTH, SECTION ON DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS. Addressing Early Childhood Emotional and Behavioral Problems. Pediatrics 2016; 138.
  35. Gleason MM, Goldson E, Yogman MW, et al. Addressing Early Childhood Emotional and Behavioral Problems. Pediatrics 2016; 138.
  36. Groenman AP, Hornstra R, Hoekstra PJ, et al. An Individual Participant Data Meta-analysis: Behavioral Treatments for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2022; 61:144.
  37. Dekkers TJ, Hornstra R, van der Oord S, et al. Meta-analysis: Which Components of Parent Training Work for Children With Attention-Deficit/Hyperactivity Disorder? J Am Acad Child Adolesc Psychiatry 2022; 61:478.
  38. Klassen A, Miller A, Raina P, et al. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999; 44:1007.
  39. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115:e749.
  40. Zwi M, Jones H, Thorgaard C, et al. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2011; :CD003018.
  41. Daley D, van der Oord S, Ferrin M, et al. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry 2014; 53:835.
  42. Goode AP, Coeytaux RR, Maslow GR, et al. Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Pediatrics 2018; 141.
  43. Fabiano GA, Pelham WE Jr, Coles EK, et al. A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. Clin Psychol Rev 2009; 29:129.
  44. Evans SW, Owens JS, Bunford N. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol 2014; 43:527.
  45. Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999; :i.
  46. Storebø OJ, Skoog M, Damm D, et al. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2011; :CD008223.
  47. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 2008; 28:783.
  48. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.
  49. Miller KJ, Wender EH. Attention deficit/hyperactivity disorder. In: Primary Pediatric Care, 4th ed, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.756.
  50. Charach A, Dashti B, Carson P, et al. Attention deficit hyperactivity disorder: Effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. AHRQ Publication No. 12-EHC003, Agency for Healthcare Research and Quality, 2011.
  51. Lovett BJ, Nelson JM. Systematic Review: Educational Accommodations for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2021; 60:448.
  52. Volpe RJ, DuPaul GJ, Jitendra AK, et al. Consultation-based academic interventions for children with attention deficit hyperactivity disorder: effects on reading and mathematics outcomes at 1-year follow-up. School Psych Rev 2009; 38:5.
  53. Evans SE, Serpell ZN, Schultz BK, et al. Cumulative benefits of secondary school-based treatment of students with attention deficit hyperactivity disorder. School Psych Rev 2007; 36:256.
  54. Jitendra AK, DuPaul GJ, Volpe RJ, et al. Consultation-based academic intervention for children with attention deficit hyperactivity disorder: school functioning outcomes. School Psych Rev 2007; 26:217.
  55. Hoza B. Peer functioning in children with ADHD. Ambul Pediatr 2007; 7:101.
  56. Cortese S, Ferrin M, Brandeis D, et al. Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 2015; 54:164.
  57. Wilkes-Gillan S, Bundy A, Cordier R, et al. A Randomised Controlled Trial of a Play-Based Intervention to Improve the Social Play Skills of Children with Attention Deficit Hyperactivity Disorder (ADHD). PLoS One 2016; 11:e0160558.
  58. Froehlich TE, Brinkman WB. Multimodal Treatment of the School-aged Child With Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr 2018; 172:109.
  59. Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol 2005; 6:262.
  60. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005; 43:831.
  61. Barkley RA. Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments. J Psychiatr Pract 2004; 10:39.
  62. Vidal R, Castells J, Richarte V, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2015; 54:275.
  63. Stein DS, Blum NJ, Barbaresi WJ. Developmental and behavioral disorders through the life span. Pediatrics 2011; 128:364.
  64. Lambez B, Harwood-Gross A, Golumbic EZ, Rassovsky Y. Non-pharmacological interventions for cognitive difficulties in ADHD: A systematic review and meta-analysis. J Psychiatr Res 2020; 120:40.
  65. United States Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd ed. November 2018. Available at: https://health.gov/paguidelines/second-edition/ (Accessed on November 19, 2018).
  66. Pontifex MB, Saliba BJ, Raine LB, et al. Exercise improves behavioral, neurocognitive, and scholastic performance in children with attention-deficit/hyperactivity disorder. J Pediatr 2013; 162:543.
  67. Memarmoghaddam M, Torbati HT, Sohrabi M, et al. Effects of a selected exercise programon executive function of children with attention deficit hyperactivity disorder. J Med Life 2016; 9:373.
  68. Ziereis S, Jansen P. Effects of physical activity on executive function and motor performance in children with ADHD. Res Dev Disabil 2015; 38:181.
  69. Chang YK, Liu S, Yu HH, Lee YH. Effect of acute exercise on executive function in children with attention deficit hyperactivity disorder. Arch Clin Neuropsychol 2012; 27:225.
  70. Pan CY, Chu CH, Tsai CL, et al. A racket-sport intervention improves behavioral and cognitive performance in children with attention-deficit/hyperactivity disorder. Res Dev Disabil 2016; 57:1.
  71. Silva AP, Prado SO, Scardovelli TA, et al. Measurement of the effect of physical exercise on the concentration of individuals with ADHD. PLoS One 2015; 10:e0122119.
  72. Kamp CF, Sperlich B, Holmberg HC. Exercise reduces the symptoms of attention-deficit/hyperactivity disorder and improves social behaviour, motor skills, strength and neuropsychological parameters. Acta Paediatr 2014; 103:709.
  73. Cerrillo-Urbina AJ, García-Hermoso A, Sánchez-López M, et al. The effects of physical exercise in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis of randomized control trials. Child Care Health Dev 2015; 41:779.
  74. Ng QX, Ho CYX, Chan HW, et al. Managing childhood and adolescent attention-deficit/hyperactivity disorder (ADHD) with exercise: A systematic review. Complement Ther Med 2017; 34:123.
  75. Bowling A, Slavet J, Miller DP, et al. Cybercycling Effects on Classroom Behavior in Children With Behavioral Health Disorders: An RCT. Pediatrics 2017; 139.
  76. Choi JW, Han DH, Kang KD, et al. Aerobic exercise and attention deficit hyperactivity disorder: brain research. Med Sci Sports Exerc 2015; 47:33.
  77. Chang YK, Hung CL, Huang CJ, et al. Effects of an aquatic exercise program on inhibitory control in children with ADHD: a preliminary study. Arch Clin Neuropsychol 2014; 29:217.
  78. Gapin JI, Labban JD, Bohall SC, et al. Acute exercise is associated with sepcific executive functions in college students with ADHD: A preliminary study. J Sport Health Sci 2014; 4:89.
  79. Ghuman JK. Restricted elimination diet for ADHD: the INCA study. Lancet 2011; 377:446.
  80. Kemp A. Food additives and hyperactivity. BMJ 2008; 336:1144.
  81. Eigenmann PA, Haenggeli CA. Food colourings, preservatives, and hyperactivity. Lancet 2007; 370:1524.
  82. Rojas NL, Chan E. Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Ment Retard Dev Disabil Res Rev 2005; 11:116.
  83. Schab DW, Trinh NH. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials. J Dev Behav Pediatr 2004; 25:423.
  84. Nigg JT, Lewis K, Edinger T, Falk M. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry 2012; 51:86.
  85. Millichap JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics 2012; 129:330.
  86. Stevens LJ, Kuczek T, Burgess JR, et al. Dietary sensitivities and ADHD symptoms: thirty-five years of research. Clin Pediatr (Phila) 2011; 50:279.
  87. Sonuga-Barke EJ, Brandeis D, Cortese S, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013; 170:275.
  88. Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled, artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child 2004; 89:506.
  89. Sampson HA, Aceves S, Bock SA, et al. Food allergy: a practice parameter update-2014. J Allergy Clin Immunol 2014; 134:1016.
  90. Bekaroğlu M, Aslan Y, Gedik Y, et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 1996; 37:225.
  91. Sorgi PJ, Hallowell EM, Hutchins HL, Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J 2007; 6:16.
  92. Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995; 62:761.
  93. Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol 2009; 51:580.
  94. Parletta N, Niyonsenga T, Duff J. Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels and Correlations with Symptoms in Children with Attention Deficit Hyperactivity Disorder, Autistic Spectrum Disorder and Typically Developing Controls. PLoS One 2016; 11:e0156432.
  95. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011; 50:991.
  96. Barragán E, Breuer D, Döpfner M. Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. J Atten Disord 2017; 21:433.
  97. Chang JP, Su KP, Mondelli V, Pariante CM. Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies. Neuropsychopharmacology 2018; 43:534.
  98. Bernstein AS, Oken E, de Ferranti S, et al. Fish, Shellfish, and Children's Health: An Assessment of Benefits, Risks, and Sustainability. Pediatrics 2019.
  99. Gillies D, Leach MJ, Perez Algorta G. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2023; 4:CD007986.
  100. National Center for Complementary and Integrative Health. Clinical Digest. Spotlight on a modality: Omega-3 fatty acids. August 2013. Available at: https://nccih.nih.gov/health/providers/digest/omega3s (Accessed on September 12, 2017).
  101. van der Oord S, Bögels SM, Peijnenburg D. The Effectiveness of Mindfulness Training for Children with ADHD and Mindful Parenting for their Parents. J Child Fam Stud 2012; 21:139.
  102. Anderson SB, Guthery AM. Mindfulness-based psychoeducation for parents of children with attention-deficit/hyperactivity disorder: an applied clinical project. J Child Adolesc Psychiatr Nurs 2015; 28:43.
  103. van de Weijer-Bergsma E, Formsma AR, de Bruin EI, Bögels SM. The Effectiveness of Mindfulness Training on Behavioral Problems and Attentional Functioning in Adolescents with ADHD. J Child Fam Stud 2012; 21:775.
  104. Kollins SH, DeLoss DJ, Cañadas E, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit Health 2020; 2:e168.
  105. Kollins SH, Childress A, Heusser AC, Lutz J. Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD. NPJ Digit Med 2021; 4:58.
  106. US Food and Drug Administration. FDA permits marketing of first game-based digital therapeutic to improve attention function in children with ADHD. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-game-based-digital-therapeutic-improve-attention-function-children-adhd?utm_campaign=061520_PR_FDA%20Permits%20Marketing%20of%20Digital%20Therapeutic%20for%20Children%20with%20ADHD&utm_medium=email&utm_source=Elo (Accessed on March 24, 2022).
  107. Roy-Byrne P, Radesky J. NEJM Journal Watch. A video game for ADHD? https://www.jwatch.org/na51019/2020/03/10/video-game-adhd?query=pfw&jwd=000101751049&jspc=US (Accessed on March 24, 2022).
  108. McGough JJ, Sturm A, Cowen J, et al. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2019; 58:403.
  109. McGough JJ, Loo SK, Sturm A, et al. An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder. Brain Stimul 2015; 8:299.
  110. US Food and Drug Administration. FDA permits marketing of first medical device for treatment of ADHD. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm636379.htm (Accessed on April 24, 2019).
  111. Grigolon RB, Blumberger DM, Daskalakis ZJ, Trevizol AP. Editorial: Transcutaneous Trigeminal Nerve Stimulation for Children With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2019; 58:392.
  112. Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002; 23:S37.
  113. Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health 2005; 41:23.
  114. Fischer M, Barkley RA, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol 1990; 58:580.
  115. Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up. II. Status of subjects without a mental disorder. Arch Gen Psychiatry 1988; 45:13.
  116. Gilmour J, Harrison C, Asadi L, et al. Natural health product-drug interactions: evolving responsibilities to take complementary and alternative medicine into account. Pediatrics 2011; 128 Suppl 4:S155.
  117. Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999; 46:977.
  118. Lilienfeld SO. Scientifically unsupported and supported interventions for childhood psychopathology: a summary. Pediatrics 2005; 115:761.
  119. Skokauskas N, McNicholas F, Masaud T, Frodl T. Complementary medicine for children and young people who have attention deficit hyperactivity disorder. Curr Opin Psychiatry 2011; 24:291.
  120. Lofthouse N, Arnold LE, Hersch S, et al. A review of neurofeedback treatment for pediatric ADHD. J Atten Disord 2012; 16:351.
  121. Weber W, Vander Stoep A, McCarty RL, et al. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA 2008; 299:2633.
  122. Vollebregt MA, van Dongen-Boomsma M, Buitelaar JK, Slaats-Willemse D. Does EEG-neurofeedback improve neurocognitive functioning in children with attention-deficit/hyperactivity disorder? A systematic review and a double-blind placebo-controlled study. J Child Psychol Psychiatry 2014; 55:460.
  123. Cortese S, Ferrin M, Brandeis D, et al. Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. J Am Acad Child Adolesc Psychiatry 2016; 55:444.
  124. Janssen TW, Bink M, Geladé K, et al. A Randomized Controlled Trial Investigating the Effects of Neurofeedback, Methylphenidate, and Physical Activity on Event-Related Potentials in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2016; 26:344.
  125. Geladé K, Janssen TW, Bink M, et al. Behavioral Effects of Neurofeedback Compared to Stimulants and Physical Activity in Attention-Deficit/Hyperactivity Disorder: A Randomized Controlled Trial. J Clin Psychiatry 2016; 77:e1270.
  126. Steiner NJ, Frenette EC, Rene KM, et al. Neurofeedback and cognitive attention training for children with attention-deficit hyperactivity disorder in schools. J Dev Behav Pediatr 2014; 35:18.
  127. Steiner NJ, Frenette EC, Rene KM, et al. In-school neurofeedback training for ADHD: sustained improvements from a randomized control trial. Pediatrics 2014; 133:483.
  128. Gevensleben H, Holl B, Albrecht B, et al. Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. J Child Psychol Psychiatry 2009; 50:780.
  129. Bink M, van Nieuwenhuizen C, Popma A, et al. Neurocognitive effects of neurofeedback in adolescents with ADHD: a randomized controlled trial. J Clin Psychiatry 2014; 75:535.
  130. Voelker R. FDA warning targets OTC chelation products. JAMA 2010; 304:2112.
  131. US Food and Drug Administration. Chelation products: Unapproved over-the-counter drugs -- consumer warning. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm229454.htm.
  132. Haslam RH, Dalby JT, Rademaker AW. Effects of megavitamin therapy on children with attention deficit disorders. Pediatrics 1984; 74:103.
  133. McClafferty H, Vohra S, Bailey M, et al. Pediatric Integrative Medicine. Pediatrics 2017; 140.
  134. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9:711.
  135. Mannuzza S, Klein RG, Bessler A, et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155:493.
  136. Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry 1985; 42:937.
  137. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50:565.
  138. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985; 24:211.
  139. Weiss G, Hechtman L, Perlman T. Hyperactives as young adults: school, employer, and self-rating scales obtained during ten-year follow-up evaluation. Am J Orthopsychiatry 1978; 48:438.
  140. Biederman J, Petty CR, Evans M, et al. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res 2010; 177:299.
  141. Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 2012; 69:1295.
  142. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48:484.
  143. Hechtman L, Swanson JM, Sibley MH, et al. Functional Adult Outcomes 16 Years After Childhood Diagnosis of Attention-Deficit/Hyperactivity Disorder: MTA Results. J Am Acad Child Adolesc Psychiatry 2016; 55:945.
  144. Roy A, Hechtman L, Arnold LE, et al. Childhood Predictors of Adult Functional Outcomes in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (MTA). J Am Acad Child Adolesc Psychiatry 2017; 56:687.
  145. Sibley MH, Arnold LE, Swanson JM, et al. Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD. Am J Psychiatry 2022; 179:142.
  146. Barbaresi WJ, Colligan RC, Weaver AL, et al. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics 2013; 131:637.
  147. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:780.
  148. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci 2001; 931:1.
  149. Lecendreux M, Konofal E, Cortese S, Faraone SV. A 4-year follow-up of attention-deficit/hyperactivity disorder in a population sample. J Clin Psychiatry 2015; 76:712.
  150. Voigt RG, Katusic SK, Colligan RC, et al. Academic Achievement in Adults with a History of Childhood Attention-Deficit/Hyperactivity Disorder: A Population-Based Prospective Study. J Dev Behav Pediatr 2017; 38:1.
  151. Hinshaw SP, Owens EB, Zalecki C, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: continuing impairment includes elevated risk for suicide attempts and self-injury. J Consult Clin Psychol 2012; 80:1041.
  152. Roy A, Hechtman L, Arnold LE, et al. Childhood Factors Affecting Persistence and Desistence of Attention-Deficit/Hyperactivity Disorder Symptoms in Adulthood: Results From the MTA. J Am Acad Child Adolesc Psychiatry 2016; 55:937.
  153. Riglin L, Collishaw S, Thapar AK, et al. Association of Genetic Risk Variants With Attention-Deficit/Hyperactivity Disorder Trajectories in the General Population. JAMA Psychiatry 2016; 73:1285.
  154. Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 2004; 35:346.e1.
  155. DiScala C, Lescohier I, Barthel M, Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998; 102:1415.
  156. Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285:60.
  157. Lam LT. Attention deficit disorder and hospitalization owing to intra- and interpersonal violence among children and young adolescents. J Adolesc Health 2005; 36:19.
  158. Pastor PN, Reuben CA. Identified attention-deficit/hyperactivity disorder and medically attended, nonfatal injuries: US school-age children, 1997-2002. Ambul Pediatr 2006; 6:38.
  159. Dalsgaard S, Østergaard SD, Leckman JF, et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015; 385:2190.
  160. Chen YY, Chen YL, Gau SS. Attention-deficit hyperactivity disorder and suicidality: The mediating effects of psychiatric comorbidities and family function. J Affect Disord 2019; 242:96.
  161. Man KK, Chan EW, Coghill D, et al. Methylphenidate and the risk of trauma. Pediatrics 2015; 135:40.
  162. Dalsgaard S, Leckman JF, Mortensen PB, et al. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry 2015; 2:702.
  163. Ghirardi L, Larsson H, Chang Z, et al. Attention-Deficit/Hyperactivity Disorder Medication and Unintentional Injuries in Children and Adolescents. J Am Acad Child Adolesc Psychiatry 2020; 59:944.
  164. Shoval G, Visoki E, Moore TM, et al. Evaluation of Attention-Deficit/Hyperactivity Disorder Medications, Externalizing Symptoms, and Suicidality in Children. JAMA Netw Open 2021; 4:e2111342.
  165. Sun S, Kuja-Halkola R, Faraone SV, et al. Association of Psychiatric Comorbidity With the Risk of Premature Death Among Children and Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry 2019; 76:1141.
  166. Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry 2006; 15:105.
  167. Curry AE, Metzger KB, Pfeiffer MR, et al. Motor Vehicle Crash Risk Among Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr 2017; 171:756.
  168. Curry AE, Yerys BE, Metzger KB, et al. Traffic Crashes, Violations, and Suspensions Among Young Drivers With ADHD. Pediatrics 2019; 143.
  169. Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 2006; 118:e704.
  170. Verster JC, Bekker EM, de Roos M, et al. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial. J Psychopharmacol 2008; 22:230.
  171. Biederman J, Fried R, Hammerness P, et al. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire. J Adolesc Health 2012; 51:601.
  172. Weiss G, Hechtman L, Perlman T, et al. Hyperactives as young adults: a controlled prospective ten-year follow-up of 75 children. Arch Gen Psychiatry 1979; 36:675.
  173. Lambert NM. Adolescent outcomes for hyperactive children. Perspectives on general and specific patterns of childhood risk for adolescent educational, social, and mental health problems. Am Psychol 1988; 43:786.
  174. Fergusson DM, Lynskey MT, Horwood LJ. Attentional difficulties in middle childhood and psychosocial outcomes in young adulthood. J Child Psychol Psychiatry 1997; 38:633.
  175. Sayal K, Washbrook E, Propper C. Childhood behavior problems and academic outcomes in adolescence: longitudinal population-based study. J Am Acad Child Adolesc Psychiatry 2015; 54:360.
  176. Fleming M, Fitton CA, Steiner MFC, et al. Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr 2017; 171:e170691.
  177. Pingault JB, Tremblay RE, Vitaro F, et al. Childhood trajectories of inattention and hyperactivity and prediction of educational attainment in early adulthood: a 16-year longitudinal population-based study. Am J Psychiatry 2011; 168:1164.
  178. Mannuzza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997; 36:1222.
  179. Lee SS, Humphreys KL, Flory K, et al. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev 2011; 31:328.
  180. Harstad E, Levy S, Committee on Substance Abuse. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics 2014; 134:e293.
  181. Molina BS, Hinshaw SP, Eugene Arnold L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry 2013; 52:250.
  182. Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 2013; 70:740.
  183. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111:179.
  184. McCabe SE, Schulenberg JE, Wilens TE, et al. Cocaine or Methamphetamine Use During Young Adulthood Following Stimulant Use for Attention-Deficit/Hyperactivity Disorder During Adolescence. JAMA Netw Open 2023; 6:e2322650.
  185. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 2004; 45:195.
Topic 623 Version 68.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟